JAN (NYSE:JAN) Stock Has Average Target Price of $32.44

JAN (NYSE:JAN) has earned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $32.44.

A number of brokerages have recently issued reports on JAN. Scotiabank raised their target price on shares of JAN from $31.00 to $33.00 and gave the stock a “sector outperform” rating in a research report on Thursday, September 17th. Royal Bank Of Canada raised their price objective on shares of JAN from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Monday, August 10th. Wells Fargo & Company lifted their price objective on shares of JAN from $33.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, September 1st. JPMorgan Chase & Co. increased their target price on shares of JAN from $30.00 to $34.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 18th. Finally, Raymond James Financial initiated coverage on JAN in a report on Tuesday, June 16th. They set a “strong-buy” rating and a $34.00 price target on the stock.

JAN News Summary

Here are the key news stories impacting JAN this week:

• Neutral Sentiment: The recent articles focus on unrelated companies, including SolarMax Technology, Tevogen, Tilray, and several other stocks. None reports an operational update, earnings release, analyst action, financing, or other material development involving JanOne.
• Neutral Sentiment: Investors may therefore be responding to broader market activity or technical trading. JAN is trading near its 200-day moving average, while its 50-day average remains higher, suggesting mixed momentum.
• Negative Sentiment: The company’s latest reported quarter showed adjusted earnings of $0.05 per share, below the $0.23 analyst consensus, despite revenue of $216.5 million exceeding expectations and rising 45.4% year over year. The earnings miss remains a potential overhang.

JAN Price Performance

Shares of JAN opened at $28.08 on Tuesday. JAN has a 1-year low of $22.76 and a 1-year high of $32.83. The firm has a fifty day moving average price of $30.20 and a 200 day moving average price of $27.93.

JAN (NYSE:JAN) last posted its earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The firm had revenue of $216.46 million during the quarter, compared to analyst estimates of $203.32 million. The business’s revenue was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. As a group, equities analysts expect that JAN will post 0.97 EPS for the current fiscal year.

JAN Dividend Announcement

The company also recently disclosed a monthly dividend, which will be paid on Tuesday, December 29th. Investors of record on Friday, December 18th will be given a $0.0475 dividend. This represents a $0.57 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Friday, December 18th.

Institutional Trading of JAN

Several hedge funds and other institutional investors have recently made changes to their positions in the company. WINTON GROUP Ltd acquired a new position in JAN during the second quarter worth $2,985,000. Engineers Gate Manager LP purchased a new stake in JAN during the second quarter worth $15,274,000. Greenland Capital Management LP purchased a new position in shares of JAN in the second quarter valued at $575,000. Readystate Asset Management LP purchased a new stake in shares of JAN in the 2nd quarter worth about $1,724,000. Finally, Wellington Management Group LLP acquired a new stake in JAN in the 2nd quarter valued at about $8,739,000. Hedge funds and other institutional investors own 6.27% of the company’s stock.

JAN Company Profile

JanOne Inc (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.